Avita Medical (ASX:AVH) reported a net loss of $16.2 million, or $0.62 per share, for the third quarter, compared with a net loss of $8.7 million, or $0.34 per share, a year ago, according to a Nov. 8 filing with the Australian bourse.
Total revenue for the three months ended Sept. 30 was $19.5 million, an increase of 44% from $13.6 million in the year-ago period on the strength of Avita's cell harvesting device, Recell GO.
The regenerative medicine company expects commercial revenue for the fourth quarter to rise 58% to 72% year on year to a range of $22.3 million to $24.3 million.
Fiscal 2024 revenue is expected to be within the previous guidance of $68 million to $70 million, reflecting an annual increase of 37% to 41%. The company also reaffirmed guidance of achieving cashflow break-even and GAAP profitability no later than the end of the third quarter of fiscal 2025, the filing stated.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。